AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39492701 — intervention group
Group type: COMPARATOR
Intervention: Standard dual antiplatelet therapy (DAPT) with clopidogrel plus aspirin for 12 months
Number of subjects: 0
Study 39492841 — intervention group
Group type: EXPERIMENTAL
Intervention: cadonilimab at a dosage of 6 mg/kg on day 1 of each 21-day cycle combined with intravenous liposomal irinotecan at a dosage of 70 mg/m2
Number of subjects: 51
Study 39492851 — intervention group
Group type: EXPERIMENTAL
Intervention: Expanded CHW model
Number of subjects: 2886
Study 39492851 — intervention group
Group type: COMPARATOR
Intervention: Existing CHW model
Number of subjects: 2886
Study 39493113 — intervention group
Group type: EXPERIMENTAL
Intervention: Cone beam CT (CBCT)-based online adaptive radiotherapy (OART)
Number of subjects: 1
Study 39493113 — intervention group
Group type: COMPARATOR
Intervention: Conventional stereotactic body radiotherapy (SBRT)
Number of subjects: 1
Study 39493261 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy with CADe + ECV
Number of subjects: 90
Study 39493261 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy with CADe
Number of subjects: 90
Study 39493261 — intervention group
Group type: COMPARATOR
Intervention: Standard colonoscopy
Number of subjects: 90
Study 39493359 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartwatch + cardiac patch monitor
Number of subjects: 95
Study 39493359 — intervention group
Group type: COMPARATOR
Intervention: Cardiac patch monitor only
Number of subjects: 95
Study 39493410 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid telemedicine approach with in-person follow-ups
Number of subjects: 46
Study 39493410 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face visits
Number of subjects: 46
Study 39493541 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal breastmilk expression (aBME)
Number of subjects: 7
Study 39493627 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-rehabilitation (TR)
Number of subjects: 55
Study 39493627 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation (CT)
Number of subjects: 55
Study 39493634 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise programme guided by the COVIDReApp system
Number of subjects: 100
Study 39493634 — intervention group
Group type: COMPARATOR
Intervention: Paper format exercise programme
Number of subjects: 100
Study 39493729 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent error augmentation physical therapy (F-EA-PT)
Number of subjects: 100
Study 39493729 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care physical therapy (SOC-PT)
Number of subjects: 100
Study 39493888 — intervention group
Group type: EXPERIMENTAL
Intervention: guselkumab (100 mg every 4 weeks (Q4W) or at Weeks 0, 4, and then Q8W)
Number of subjects: 739
Study 39493888 — intervention group
Group type: EXPERIMENTAL
Intervention: guselkumab
Number of subjects: 739
Study 39493888 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 739
Study 39494083 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment at T2 (2020-2021) using WHOQOL-BREF
Number of subjects: 284
Study 39494083 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment at T1 (2015-2016) and T2 (2020-2021) using WHOQOL-BREF
Number of subjects: 284
Study 39494309 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized nutritional intervention using the Nutrition Care Process (NCP) model
Number of subjects: 2050
Study 39494309 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional diagnoses in the intake domain
Number of subjects: 2050
Study 39494565 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training (3 times/week, 65%-85% peak oxygen uptake)
Number of subjects: 54
Study 39494577 — intervention group
Group type: EXPERIMENTAL
Intervention: OCT guidance
Number of subjects: 588
Study 39494577 — intervention group
Group type: COMPARATOR
Intervention: Angiography guidance
Number of subjects: 588
Study 39494607 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral iron replacement therapy (IRT) with probiotics, specific dosage and duration not mentioned.
Number of subjects: 0
Study 39494607 — intervention group
Group type: COMPARATOR
Intervention: Oral iron replacement therapy (IRT) without probiotics, specific dosage and duration not mentioned.
Number of subjects: 0
Study 39494843 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention villages implementing strategies developed in Phase 2 for 1 year
Number of subjects: 48
Study 39494843 — intervention group
Group type: COMPARATOR
Intervention: Usual care in control villages
Number of subjects: 48
Study 39495056 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitros NT-proBNP II assay
Number of subjects: 2200
Study 39495136 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-annual screening with ultrasound ± alpha-fetoprotein (arm A)
Number of subjects: 5500
Study 39495136 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-annual screening with GALAD (arm B)
Number of subjects: 5500
Study 39495140 — intervention group
Group type: COMPARATOR
Intervention: ECC5004 (1-300 mg single doses in healthy volunteers; 5, 10, 30, and 50 mg multiple daily doses in patients with T2DM for 28 days)
Number of subjects: 0
Study 39495140 — intervention group
Group type: EXPERIMENTAL
Intervention: ECC5004
Number of subjects: 0
Study 39495154 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorecivivint (LOR) 0.07 mg
Number of subjects: 0
Study 39495154 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39495175 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant immunochemotherapy (NAIC)
Number of subjects: 75
Study 39495243 — intervention group
Group type: EXPERIMENTAL
Intervention: Inappropriate DOAC dosing
Number of subjects: 432
Study 39495243 — intervention group
Group type: COMPARATOR
Intervention: Appropriate DOAC dosing
Number of subjects: 432
Study 39495243 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-rivaroxaban DOACs
Number of subjects: 432
Study 39495243 — intervention group
Group type: EXPERIMENTAL
Intervention: Old age
Number of subjects: 432
Study 39495243 — intervention group
Group type: EXPERIMENTAL
Intervention: Anemia
Number of subjects: 432
Study 39495467 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitiperstat 2.5 mg
Number of subjects: 32
Study 39495467 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitiperstat 5 mg
Number of subjects: 32
Study 39495467 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitiperstat 10 mg
Number of subjects: 32
Study 39495467 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 32
Study 39495467 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitiperstat (all doses)
Number of subjects: 32
Study 39495531 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferiprone 15 mg/kg twice a day
Number of subjects: 81
Study 39495531 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 39495569 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation treatment
Number of subjects: 0
Study 39495569 — intervention group
Group type: COMPARATOR
Intervention: Control group (no anticoagulation)
Number of subjects: 0
Study 39495582 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher risk interventions (sphincterotomy, sphincteroplasty, precut sphincterotomy, and/or needle-knife access)
Number of subjects: 8517
Study 39495582 — intervention group
Group type: EXPERIMENTAL
Intervention: P2Y12 inhibitors
Number of subjects: 8517
Study 39495582 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 8517
Study 39495582 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 8517
Study 39495582 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 8517
Study 39495582 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 8517
Study 39495582 — intervention group
Group type: EXPERIMENTAL
Intervention: Sphincterotomy
Number of subjects: 8517
Study 39495582 — intervention group
Group type: EXPERIMENTAL
Intervention: CSPEB
Number of subjects: 8517
Study 39495835 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiographic parameters
Number of subjects: 0
Study 39495965 — intervention group
Group type: EXPERIMENTAL
Intervention: Survodutide (3.6 or 6.0 mg, once-weekly subcutaneous injections)
Number of subjects: 726
Study 39495965 — intervention group
Group type: COMPARATOR
Intervention: Placebo (once-weekly subcutaneous injections)
Number of subjects: 726
Study 39495999 — intervention group
Group type: EXPERIMENTAL
Intervention: Video Conference (VC) group
Number of subjects: 30
Study 39495999 — intervention group
Group type: COMPARATOR
Intervention: Video-Based Home Exercise (VBHE) group
Number of subjects: 30
Study 39495999 — intervention group
Group type: COMPARATOR
Intervention: Comparison of VC vs VBHE
Number of subjects: 30
Study 39496043 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume training resistance training (LVT; n=15, 3 sessions of 12 exercises per week)
Number of subjects: 45
Study 39496043 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-volume training resistance training (MVT; n=15; 4 sessions of 12 exercises per week)
Number of subjects: 45
Study 39496043 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume training resistance training (HVT; n=15; 5 sessions of 12 exercises per week)
Number of subjects: 45
Study 39496135 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% (CAB) gel
Number of subjects: 6
Study 39496135 — intervention group
Group type: COMPARATOR
Intervention: Vehicle gel
Number of subjects: 6
Study 39496153 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat index between over 27°C and 32°C
Number of subjects: 61
Study 39496153 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat index over 32°C
Number of subjects: 61
Study 39496153 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower health literacy
Number of subjects: 61
Study 39496153 — intervention group
Group type: EXPERIMENTAL
Intervention: Better self-reported protective behavior
Number of subjects: 61
Study 39496153 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower self-efficacy
Number of subjects: 61
Study 39496153 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher somatosensory amplification
Number of subjects: 61
Study 39496199 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental lozenges containing laccase enzyme and green coffee extract (with flavor)
Number of subjects: 156
Study 39496199 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental lozenges containing laccase enzyme and green coffee extract (without flavor)
Number of subjects: 156
Study 39496199 — intervention group
Group type: COMPARATOR
Intervention: Placebo lozenges
Number of subjects: 156
Study 39496199 — intervention group
Group type: COMPARATOR
Intervention: No-product control
Number of subjects: 156
Study 39496364 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training with biofeedback and home training for 6 months.
Number of subjects: 0
Study 39496364 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention during the 6 months).
Number of subjects: 0
Study 39496367 — intervention group
Group type: EXPERIMENTAL
Intervention: ISMiHealth software intervention with screening recommendations for infectious diseases and FGM.
Number of subjects: 35
Study 39496367 — intervention group
Group type: COMPARATOR
Intervention: Current routine practice in control centres.
Number of subjects: 35
Study 39497010 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral lymph node dissection (LLND) in non-CRT patients
Number of subjects: 566
Study 39497010 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral lymph node dissection (LLND) in nCRT patients
Number of subjects: 566
Study 39497010 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathological obturator node metastasis
Number of subjects: 566
Study 39497088 — intervention group
Group type: EXPERIMENTAL
Intervention: ASD patients
Number of subjects: 100
Study 39497092 — intervention group
Group type: EXPERIMENTAL
Intervention: High bronchodilator response (BDR) group (N = 277)
Number of subjects: 1134
Study 39497092 — intervention group
Group type: COMPARATOR
Intervention: Low bronchodilator response (BDR) group (N = 278)
Number of subjects: 1134
Study 39497092 — intervention group
Group type: COMPARATOR
Intervention: LOCCS cohort (adult asthma cohort)
Number of subjects: 1134
Study 39497332 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cone-beam computed tomography (CBCT) protocol
Number of subjects: 11
Study 39497332 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose cone-beam computed tomography (CBCT) protocol
Number of subjects: 11
Study 39497468 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Number of subjects: 0
Study 39497468 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide (≥20% weight reduction)
Number of subjects: 0
Study 39497537 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable hormonal contraception, frequency of sex in the prior 3 months, residing in a community with HIV prevalence of 29% or higher (females)
Number of subjects: 8551
Study 39497537 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-long-term relationships with the most recent partner, community HIV prevalence of 34% or higher (males)
Number of subjects: 8551
Study 39497616 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal pegcetacoplan 15 mg monthly
Number of subjects: 1501
Study 39497616 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal pegcetacoplan 15 mg every other month (EOM)
Number of subjects: 1501
Study 39497616 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 1501
Study 39497751 — intervention group
Group type: EXPERIMENTAL
Intervention: Crizanlizumab 5.0 mg/kg
Number of subjects: 57
Study 39497751 — intervention group
Group type: EXPERIMENTAL
Intervention: Crizanlizumab 7.5 mg/kg
Number of subjects: 57
Study 39497836 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranial surgery (260 subjects; 65% decompressive craniectomy, 23% craniotomy, 12% other surgery)
Number of subjects: 2032
Study 39497836 — intervention group
Group type: EXPERIMENTAL
Intervention: Decompressive craniectomy
Number of subjects: 2032
Study 39497836 — intervention group
Group type: EXPERIMENTAL
Intervention: Earlier time-to-craniectomy
Number of subjects: 2032
Study 39497947 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month TTR 110-140 mm Hg
Number of subjects: 7134
Study 39497947 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month TTR >0.65
Number of subjects: 7134
Study 39497947 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month TTR index cutoff of 0.65
Number of subjects: 7134
Study 39498312 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart-Smile Training (HST) intervention group
Number of subjects: 50
Study 39498312 — intervention group
Group type: COMPARATOR
Intervention: Waitlist group
Number of subjects: 50
Study 39498340 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin (0.25 mg every other day) combined with csDMARDs for 6 months
Number of subjects: 60
Study 39498340 — intervention group
Group type: COMPARATOR
Intervention: Placebo combined with csDMARDs for 6 months
Number of subjects: 60
Study 39498349 — intervention group
Group type: EXPERIMENTAL
Intervention: New-generation mask (AirFit F30i or AirFit N30i)
Number of subjects: 215
Study 39498443 — intervention group
Group type: EXPERIMENTAL
Intervention: AAC + LPO (Ask-Advise-Connect + Longitudinal Proactive Outreach)
Number of subjects: 2000
Study 39498443 — intervention group
Group type: COMPARATOR
Intervention: AAC (Ask-Advise-Connect)
Number of subjects: 2000
Study 39498574 — intervention group
Group type: EXPERIMENTAL
Intervention: Male patients
Number of subjects: 4441
Study 39498574 — intervention group
Group type: EXPERIMENTAL
Intervention: Female patients
Number of subjects: 4441
Study 39498781 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine (8 to 12 mg twice daily, total 16 mg to 24 mg/day)
Number of subjects: 10990
Study 39498822 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dialysate sodium (< 138 mM)
Number of subjects: 509
Study 39499011 — intervention group
Group type: EXPERIMENTAL
Intervention: 68 Ga-HBED-CC-exendin-4
Number of subjects: 19
Study 39499011 — intervention group
Group type: COMPARATOR
Intervention: 68 Ga-NOTA-exendin-4
Number of subjects: 19
Study 39499142 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) 400 mg twice daily for 6 months
Number of subjects: 80
Study 39499142 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 39499299 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab and idelalisib
Number of subjects: 38
Study 39499299 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 38
Study 39499309 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 1000 mg
Number of subjects: 107
Study 39499309 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 400 mg
Number of subjects: 107
Study 39499373 — intervention group
Group type: EXPERIMENTAL
Intervention: SP-CNN framework for segmenting and modeling lenticulostriate arteries (LSAs)
Number of subjects: 50
Study 39499377 — intervention group
Group type: EXPERIMENTAL
Intervention: Totally laparoscopic distal gastrectomy (TLDG)
Number of subjects: 442
Study 39499377 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopy-assisted distal gastrectomy (LADG)
Number of subjects: 442
Study 39499437 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual patient education sessions (2 sessions)
Number of subjects: 120
Study 39499437 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of individual session at baseline and group session 3 months later
Number of subjects: 120
Study 39499486 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab and bevacizumab
Number of subjects: 39
Study 39499492 — intervention group
Group type: EXPERIMENTAL
Intervention: pembrolizumab + chemotherapy
Number of subjects: 0
Study 39499492 — intervention group
Group type: COMPARATOR
Intervention: chemotherapy
Number of subjects: 0
Study 39499517 — intervention group
Group type: EXPERIMENTAL
Intervention: PFMT with home-based pressure-mediated biofeedback device
Number of subjects: 452
Study 39499517 — intervention group
Group type: COMPARATOR
Intervention: Home-based PFMT
Number of subjects: 452
Study 39499551 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior change communication mobile messages over a 14-day period
Number of subjects: 100
Study 39499551 — intervention group
Group type: COMPARATOR
Intervention: e-voucher for LLINs
Number of subjects: 100
Study 39499912 — intervention group
Group type: EXPERIMENTAL
Intervention: Storm-Heroes (social game)
Number of subjects: 79
Study 39499912 — intervention group
Group type: COMPARATOR
Intervention: A Smoking Prevention Interactive Experience (ASPIRE; nonsocial program)
Number of subjects: 79
Study 39499920 — intervention group
Group type: EXPERIMENTAL
Intervention: High effort resistance exercise
Number of subjects: 15
Study 39499920 — intervention group
Group type: EXPERIMENTAL
Intervention: Low effort resistance exercise
Number of subjects: 15
Study 39499920 — intervention group
Group type: COMPARATOR
Intervention: Sedentary (control) session
Number of subjects: 15
Study 39499921 — intervention group
Group type: EXPERIMENTAL
Intervention: CHALO! 2.0 (a theory-based multilevel intervention delivered in part through WhatsApp)
Number of subjects: 1000
Study 39499921 — intervention group
Group type: COMPARATOR
Intervention: Attention-matched SMT-based control (including a digital coupon for free HIV testing)
Number of subjects: 1000
Study 39499921 — intervention group
Group type: COMPARATOR
Intervention: Digital coupon-only control
Number of subjects: 1000
Study 39500096 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based mental healthcare (CBMHC) service package
Number of subjects: 1215
Study 39500096 — intervention group
Group type: COMPARATOR
Intervention: Routine maternal care
Number of subjects: 1215
Study 39500130 — intervention group
Group type: EXPERIMENTAL
Intervention: C-peptide levels
Number of subjects: 431
Study 39500130 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI increase
Number of subjects: 431
Study 39500130 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline prevalence of IAH
Number of subjects: 431
Study 39500130 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of new IAH
Number of subjects: 431
Study 39500130 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of reversal of IAH
Number of subjects: 431
Study 39500299 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended cognitive behavioural intervention (combination of a web-based program and sessions with a psychologist)
Number of subjects: 34
Study 39500299 — intervention group
Group type: COMPARATOR
Intervention: Guided web-based intervention (active control group)
Number of subjects: 34
Study 39500494 — intervention group
Group type: EXPERIMENTAL
Intervention: CytoSorb therapy
Number of subjects: 0
Study 39500603 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial alteplase after mechanical thrombectomy (MT)
Number of subjects: 0
Study 39500603 — intervention group
Group type: COMPARATOR
Intervention: Mechanical thrombectomy (MT)
Number of subjects: 0
Study 39500789 — intervention group
Group type: EXPERIMENTAL
Intervention: nnUNet AI model
Number of subjects: 0
Study 39500883 — intervention group
Group type: EXPERIMENTAL
Intervention: JMT103 (2 mg/kg) administered subcutaneously every four weeks, with loading doses on days 8 and 15.
Number of subjects: 139
Study 39500896 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincristine treatment
Number of subjects: 1100
Study 39500896 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1100
Study 39500957 — intervention group
Group type: EXPERIMENTAL
Intervention: CSD with gradually decreasing sweetness levels (StepR)
Number of subjects: 0
Study 39500957 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced sweetness test CSD (DirR)
Number of subjects: 0
Study 39500957 — intervention group
Group type: COMPARATOR
Intervention: Control (full sweetness CSD)
Number of subjects: 0
Study 39500957 — intervention group
Group type: EXPERIMENTAL
Intervention: StepR and DirR
Number of subjects: 0
Study 39501183 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg aspirin daily
Number of subjects: 15480
Study 39501183 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g omega-3 fatty acids daily
Number of subjects: 15480
Study 39501183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15480